Case Details
- Citation: [2016] SGHC 106
- Case Title: Warner-Lambert Company LLC v Novartis (Singapore) Pte Ltd
- Court: High Court of the Republic of Singapore
- Coram: George Wei J
- Date of Decision: 26 May 2016
- Case Number: Suit No 390 of 2015 (Summons No 4136 of 2015)
- Procedural Context: Application for leave to amend patent claims under s 83(1) of the Patents Act (Cap 221, 2005 Rev Ed)
- Plaintiff/Applicant: Warner-Lambert Company LLC
- Defendant/Respondent: Novartis (Singapore) Pte Ltd
- Counsel for Plaintiff: Stanley Lai Tze Chang, SC, Gloria Goh En-Ci and Clara Tung Yi Lin (Allen & Gledhill LLP)
- Counsel for Defendant: Suhaimi Bin Lazim and Chow Jian Hong (Mirandah Law LLP)
- Legal Areas: Patents and Inventions — Industrial application; Patents and Inventions — Novelty
- Statutes Referenced: Patents Act (Cap 221, 2005 Rev Ed) including ss 25(5), 36, 38, 83(1), 84(3); Medicines Act (Cap 176, 1985 Rev Ed) s 12A(3)(a); UK Patents Act 1977; (as referenced) A of the UK Patents Act 1977
- Secondary Sources / Guides Referenced: CIPA Guide to the Patents Act (Paul G Cole gen ed) (Sweet & Maxwell, 7th Ed, 2011); Terrell on the Law of Patents (17th Ed, 2010)
- Related Appellate Note: Appeal to this decision in Civil Appeal No 121 of 2016 dismissed by the Court of Appeal on 1 August 2017 (see [2017] SGCA 45)
- Judgment Length: 29 pages, 16,981 words
Summary
Warner-Lambert Company LLC v Novartis (Singapore) Pte Ltd concerned an application by a pharmaceutical patent owner for leave to amend its Singapore patent claims while infringement proceedings were pending. The patent related to pregabalin (marketed as Lyrica) and claimed a monopoly over the use of pregabalin for treating pain. As the patent approached the end of its 20-year term, the defendant sought product licences from Singapore’s Health Sciences Authority (HSA), and the patent owner commenced infringement proceedings and then applied to amend its claims to address validity objections.
The High Court (George Wei J) dismissed the patent owner’s application for leave to amend. The court held that the proposed amendments—designed to shift from a method-of-treatment claim to a “Swiss-style” claim format—failed to satisfy the statutory constraints governing amendments, including the prohibition on adding “additional matter” and the requirement that amendments not extend the protection conferred by the patent. The court also emphasised that amendment applications are not a vehicle to cure a patent’s invalidity where the proposed changes do not properly align with the patent’s original disclosure and claim scope.
What Were the Facts of This Case?
The plaintiff, Warner-Lambert Company LLC, owned a Singapore patent granted in 2000 based on an international application filed on 16 July 1997. The patent claimed a monopoly over the use of pregabalin for the treatment of pain. In practice, the plaintiff manufactured and distributed Lyrica, a product containing pregabalin as its active ingredient. Lyrica had been approved by the HSA for treating neuropathic pain and chronic pain disorders, including fibromyalgia.
Under Singapore patent law, patents are protected for a term of 20 years from the filing date of the application (s 36 of the Patents Act). By 2015, the patent was nearing the end of its term. In parallel, the plaintiff held equivalent patents in other jurisdictions, derived from the same international filing. This cross-jurisdictional context mattered because the plaintiff’s proposed amendments were framed to align with claim formats used elsewhere, particularly the “Swiss-style” format commonly associated with second medical use claims in European practice.
On 23 March 2015, the plaintiff received notice that the defendant had applied to the HSA for product licences for pregabalin products. The notice was made pursuant to s 12A(3)(a) of the Medicines Act, which allows certain regulatory steps to be taken in advance of patent expiry while preserving the patent owner’s ability to seek declarations on infringement. In the notice, the defendant alleged that the plaintiff’s patent would not be infringed by the acts for which the product licences were sought.
On 21 April 2015, the plaintiff commenced an action against the defendant seeking, among other relief, a declaration that the defendant’s intended acts would infringe the patent. The plaintiff then notified the defendant of its intention to apply to amend the patent on 5 May 2015. The defendant filed its defence and counterclaim on 2 June 2015, counterclaiming revocation on the basis that the patent was invalid for claiming a monopoly over methods of treatment of the human or animal body, which are not patentable in Singapore. The plaintiff’s proposed amendments were advertised on 29 June 2015, and the defendant opposed the amendments on 24 July 2015. The plaintiff then brought the present application for leave to amend on 26 August 2015.
What Were the Key Legal Issues?
The central issue was whether the plaintiff should be granted leave to amend its patent under s 83(1) of the Patents Act. Amendment in this context is tightly controlled because it affects the scope of the monopoly granted by the patent and can prejudice third parties. The court therefore had to determine the proper legal framework for assessing amendments when validity is already in issue in pending proceedings.
A second cluster of issues concerned the substantive requirements for patentability and the “futility” argument. The defendant contended that even if the amendments were allowed, the amended patent would still fail to meet the requirements of novelty, inventive step, and industrial application. The court had to decide whether it should assess validity at the amendment stage, or whether it should leave validity questions for the trial of the infringement action.
Finally, the court had to consider statutory limits on amendments, particularly s 84(3) of the Patents Act. This provision prevents amendments that would (i) disclose additional matter not originally contained in the specification, or (ii) extend the protection conferred by the patent. The court also considered whether discretionary factors—such as delay, fairness, and disclosure—should lead it to refuse leave.
How Did the Court Analyse the Issues?
George Wei J began by clarifying the procedural and legal “gateway” for amendment. The application was governed by s 83 of the Patents Act. The court noted that the Registrar’s general power to allow amendments under s 38 was inapplicable where there were pending court proceedings in which the validity of the patent had been put in issue. In such circumstances, the amendment application must be brought under s 83(1). The judge also drew a comparison with the UK Patents Act 1977, noting that similar provisions exist there for cases where validity could have been put in issue.
The court then set out the amendment principles. The power to amend is circumscribed by s 84(3), which bars amendments that add additional matter or extend the protection conferred. In addition, amendments must satisfy the “base-line criteria” in s 25(5), including that the claims be clear and concise. The court referred to established authority on patent amendment discretion, including Trek Technology (Singapore) Pte Ltd v FE Global Electronics Pte Ltd and other and other suits [2005] 3 SLR(R) 389 (“FE Global (HC)”) for the base-line criteria, and Smith Kline & French Laboratories v Evans Medical Limited [1989] FSR 561 for the discretionary factors guiding whether to allow or disallow proposed amendments.
Before turning to novelty and industrial application, the judge addressed a logically anterior question: whether the court should consider the validity of the proposed amended patent when deciding whether to grant leave to amend. The defendant argued that the court should assess whether the amended patent would still be invalid, and therefore treat the amendment as futile. The judge examined Ship’s Equipment Centre Bremen GmbH v Fuji Trading (Singapore) Pte Ltd and others and another suit [2015] 4 SLR 781 (“Ship’s Equipment”), where the court had rejected a similar “cart before the horse” approach. In Ship’s Equipment, the court had held that it was inappropriate to hear validity together with the amendment application where validity was scheduled for later in the proceedings.
Agreeing with Ship’s Equipment, the judge held that it was inappropriate to conflate the amendment hearing with a full validity determination. Even though the court might refuse an amendment if it clearly left the patent invalid, the judge found that this was not the case on the material before him. The parties intended to adduce expert evidence on validity of the proposed amendments, and the court considered it more expedient to leave validity questions to the trial where they could be properly ventilated. The defendant would not be prejudiced because it would have ample opportunity to challenge validity after the amendment application was disposed of.
In doing so, the judge also addressed the defendant’s reliance on two UK authorities referenced in Terrell on the Law of Patents: Texas Instruments Ltd v Hyundai Electronics UK Ltd and Richardson-Vicks Inc’s Patent. The judge’s approach reflected a careful calibration: while the court can consider futility in clear cases, it should not conduct a premature validity trial at the amendment stage where the issues are complex and require expert evidence.
Having determined that validity should not be fully assessed at the amendment stage, the court turned to the statutory limits in s 84(3). The proposed amendments were, in essence, a change in claim format. The plaintiff sought to replace a claim to a method of treatment with a “Swiss-style” claim, generally expressed as “the use of compound X in the manufacture of a medicament for a specified (and new) therapeutic use Y.” This was intended to address the defendant’s argument that the granted patent claimed non-patentable methods of treatment of the human body.
However, the court found that the proposed amendments fell foul of s 84(3). The judge reasoned that the amendments would result in either (i) the disclosure of additional matter beyond what was originally disclosed in the patent specification, and/or (ii) an extension of the protection conferred. The Swiss-style format, while often used to capture second medical uses in jurisdictions that permit such claims, cannot be introduced in a way that effectively broadens the patentee’s monopoly or adds subject matter not originally and directly derivable from the application as filed. The court’s analysis therefore focused on the relationship between the proposed amended claims and the original disclosure and claim scope.
In addition, the court considered discretionary grounds. The defendant argued that the plaintiff should be refused leave because of unreasonable delay, because the plaintiff was seeking an unfair advantage from a patent it knew (or should have known) was invalid, and because the plaintiff failed to make full disclosure of relevant matters regarding the proposed amendments. While the judgment’s excerpt does not reproduce the full detail of the court’s findings on each discretionary factor, the overall structure indicates that the court treated these as reinforcing reasons to refuse amendment, particularly where the amendments were aimed at curing a fundamental patentability defect rather than refining claims within the original disclosure.
What Was the Outcome?
The High Court dismissed the plaintiff’s application for leave to amend its patent. Practically, this meant that the patent owner could not proceed with the proposed Swiss-style claim amendments in the form sought. The infringement action and the defendant’s counterclaim for revocation would therefore continue on the basis of the existing claims, subject to the trial process and the parties’ expert evidence.
The decision also carried forward the procedural consequence that validity questions would be addressed in the main action rather than being resolved at the amendment stage. The LawNet editorial note further indicates that the plaintiff’s appeal was dismissed by the Court of Appeal on 1 August 2017 (Civil Appeal No 121 of 2016), confirming the High Court’s refusal to allow the amendments.
Why Does This Case Matter?
This case is significant for patent practitioners because it illustrates the strict boundaries governing amendments under Singapore law, especially where validity is already in issue. The court’s insistence on the proper procedural sequencing—amendment first under s 83, with validity questions left for trial unless clearly futile—provides guidance on how amendment hearings should be conducted and what evidential burdens parties can expect.
Substantively, the case underscores that claim-format changes (including adoption of Swiss-style “second medical use” language) do not automatically overcome patentability or statutory amendment constraints. Even where the original patent may have been drafted in a way that is vulnerable to a “methods of treatment” objection, the patentee cannot necessarily cure that vulnerability by re-labelling the claim in a manner that introduces additional matter or broadens the monopoly. The s 84(3) prohibition is a powerful constraint: amendments must remain anchored to the original disclosure and must not extend protection.
For pharmaceutical patent owners and generic challengers alike, the decision also highlights the strategic interaction between regulatory steps (HSA product licence applications under the Medicines Act) and patent litigation. Patent owners must be careful in how they respond to validity challenges and should not assume that late-stage amendments near patent expiry will be permitted, particularly where delay, fairness, and disclosure concerns arise.
Legislation Referenced
- Patents Act (Cap 221, 2005 Rev Ed), including ss 25(5), 36, 38, 83(1), 84(3)
- Medicines Act (Cap 176, 1985 Rev Ed) s 12A(3)(a)
- UK Patents Act 1977 (as referenced, including provisions analogous to amendment/validity sequencing)
Cases Cited
- [2016] SGHC 106 (the present case)
- [2017] SGCA 45 (Court of Appeal dismissal of the appeal)
- Ship’s Equipment Centre Bremen GmbH v Fuji Trading (Singapore) Pte Ltd and others and another suit [2015] 4 SLR 781
- Trek Technology (Singapore) Pte Ltd v FE Global Electronics Pte Ltd and other and other suits [2005] 3 SLR(R) 389
- Smith Kline & French Laboratories v Evans Medical Limited [1989] FSR 561
- Texas Instruments Ltd v Hyundai Electronics UK Ltd (1999) 22(12) IPD 22116 (Ch D (Patents Ct))
- Richardson-Vicks Inc’s Patent [1995] RPC 568
Source Documents
This article analyses [2016] SGHC 106 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.